Brutalist Biotech

• Ronovo Surgical raises $67M for modular laparoscopic robot with J&J backing (9h)
• OraSure comes under investor pressure, with potential proxy fight: report (10h)
• FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims (11h)
• Pfizer vet takes CEO post at new, phase 3-ready regenerative medicine biotech (12h)
• Eli Lilly invites biotechs to use its new AI platform to help develop their own drugs (14h)
• Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed in phase 2 (18h)
• LB Pharmaceuticals aims to raise $228M-plus in IPO to fund late-stage schizophrenia study (1d)
• Microbot Medical scores FDA clearance for remote-controlled cath lab system (1d)
• After FDA rejects Saol’s ultra-rare disease prospect, the biotech urges patients to press Congress (1d)
• Regeneron’s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies (1d)
• Dianthus’ gMG prospect blooms, with phase 2 win setting up pivotal plans (1d)
• Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety (1d)
• Rapport's seizure drug hits in phase 2, sending stock soaring (1d)
• Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up (1d)
• Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators (1d)
• BioNTech, BMS tout first global data for PD-L1xVEGF bispecific, set phase 3 dose in small cell lung cancer (2d)
• Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend (3d)
• Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate (4d)
• Senseonics to retake Eversense CGM commercial control from Ascensia Diabetes Care (4d)
• Daiichi-Merck's advanced lung cancer ADC sees 48% response rate in registrational trial (4d)

• Lilly to give biotech startups access to AI tools (5h)
• Novartis to gain heart drug in $1.4B deal for Tourmaline Bio (10h)
• BioNTech says dual-acting lung cancer drug helped shrink tumors (1d)
• A new class of sleep drugs draws Wall Street’s attention (1d)
• Pfizer, BioNTech showcase new data supporting COVID booster (1d)
• New Summit data clouds approval pathway in lung cancer (1d)
• Rapport shares double on better-than-expected seizure drug data (1d)
• A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria (1d)
• Driving precision oncology development: Integrated biomarker testing solutions that deliver impact (1d)
• How sponsors are staying ahead in the obesity trial landscape (1d)
• Harnessing the power of AI to detect ATTR-CM (1d)
• FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo (4d)
• Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug (4d)
• At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves (5d)
• Atlas Venture reels in $400M to grow its biotech startups (5d)
• FDA outlines new review pathway for drugs treating ultra-rare diseases (5d)
• Sanofi’s touted eczema drug hits study goal, but data fall short of expectations (5d)
• A drug discovery startup banks $150M for immune and obesity drugs (5d)
• Biohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval (6d)
• Secretive startup Treeline unveils first clinical candidates, $200M in new funding (6d)

• Trump directs more FDA enforcement of pharma ads (3h)
• Endpoints livestream: Will the XBI ever go up again? (8h)
• Lundbeck to transfer commercial drugs to three partners in 27 markets (8h)
• HHS outlines vaccine, drug strategy in new MAHA report (8h)
• Eric Green, who the Trump administration ousted from NIH, urges optimism (9h)
• Samsung Bio secures $1.3B contract with ‘large-sized’ US pharma customer (10h)
• Regeneron and Sandoz patent deal clears path for Eylea biosimilar in 2026 (10h)
• Trump may exempt some pharma products from tariffs in future trade deals (11h)
• Ideaya touts trio of cancer drugs as it eyes spot in precision oncology market (11h)
• Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot (11h)
• Eli Lilly offers AI models to biotechs with TuneLab launch (15h)
• Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drug (15h)
• Ridge Bio raises $25M to help drugmakers come up with better ADCs (16h)
• Summit plays defense for the first time as questions loom over Phase 3 data (1d)
• New FDA approval pathway for n-of-1 therapies coming soon, Prasad says (1d)
• Pfizer reports new Covid-19 vaccine data from open-label study (1d)
• Eli Lilly’s Jaypirca shows ‘striking’ results in first-line lymphoma patients (1d)
• Dianthus’ selective complement inhibitor yields Phase 2 success in myasthenia gravis (1d)
• #WCLC25: BioNTech, Bristol Myers tout PD-L1xVEGF results in small cell lung cancer (1d)
• LB Pharma seeks $228M in proposed IPO with hopes to be industry's first since February (1d)

• Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform (5h)
• Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises (11h)
• FDA Turns Away Ultra-Rare Disease Therapy (13h)
• BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC (13h)
• Neuroscience Biotech LB Files for $228M IPO to Support Phase III Plans (13h)
• Novartis Deals in Cardio Again, Dropping $1.4B to Acquire Tourmaline (14h)
• Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’ (14h)
• As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point (22h)
• Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline (22h)
• If Data Is the New Oil, AI Is the Refinery (1d)
• Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial (1d)
• FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead (1d)
• Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill (1d)
• Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions (1d)
• WHITE PAPER: Validated devices for easy self-collection and stabilization of vaginal microbiome samples (1d)
• Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy (1d)
• Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd (1d)
• WHO Adds GLP-1s to List of Essential Medicines (1d)
• FDA Expert Panels Lack Balance in Pursuit of ‘Gold Standard Science’ (1d)
• 5 Companies Caught On a Carousel of FDA Confusion (2d)

• Monarez to testify in Senate hearing next week (31m)
• FDA pledges to crack down on DTC pharma ads (2h)
• RFK Jr. ally’s ‘smoking gun’ study on vaccines and chronic illness is fundamentally flawed (5h)
• Dozens of lawmakers urge HHS to abandon a pilot initiative for the controversial 340B program (5h)
• An API supplier in India wants you to know its metal detector is working just fine (6h)
• CMS delays rule requiring Medicare Advantage insurers to remind members of unused benefits (6h)
• Kennedy looks to add new members to federal vaccine panel (6h)
• Apple introduces smartwatch feature designed to detect high blood pressure (8h)
• MAHA Commission promotes fitness as a vital sign for children. What does that mean? (8h)
• Kennedy makes his formal pitch to fight chronic disease in new MAHA report (8h)
• Study links marijuana use during IVF to higher risk of abnormal embryos (11h)
• How Trump tax bills help health care giants avoid taxes (12h)
• Strive raises $550 million for tech-powered kidney care (12h)
• A letter from the executive editor: STAT turns 10 (12h)
• Lilly looks into gene therapies for obesity (12h)
• We’re reading about Lilly and AI modeling, cost effective obesity drugs, and much more (13h)
• A promising new treatment for a tough cancer (14h)
• Obesity drugs may be pricey, but they’re also cost-effective, analysis finds (14h)
• Lilly will let small biotechs use its AI models at no cost (15h)
• What states will be next to end school vaccine requirements? (18h)

• Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation (10h)
• CHARM Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitors for AML (10h)
• Ketryx Gets $39 Million to Expand AI Compliance Infrastructure for Life Sciences (11h)
• Enveda Secures $150M Series D, Advances Lead Program & Adds Ex-Pfizer R&D Chief to Board (13h)
• Lilly Offers Biotechs Access to AI Models Trained on $1B in Proprietary Drug Discovery Data (13h)
• Proscia Launches New AI Pathology Platform to Link Patients With Drug Trials (14h)
• LatchBio Publishes 25-Million-Cell Open-Source Spatial Transcriptomics Atlas (16h)
• Digital Twins in Rare Diseases: From Virtual Trials to Personalized Care (1d)
• Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains (2w)
• Immunai Opens Free Single-Cell Sequencing Program for Academic Labs (3w)
• Innovatrix and Opyl Partner to Launch AI-Driven Insurance for Clinical Trial Failure (3w)
• KYORIN Pharmaceutical Adopts AI Drug Discovery Platform From Elix (3w)
• How AI Is Transforming Medicinal Chemistry Between Discovery and Manufacture (3w)
• Ginkgo, Inductive Bio, and Tangible Scientific Connect AI Models with Automated Labs for Drug Discovery (3w)
• Silicon Valley’s Molecular Devices Brings AI to Brain Organoid Culture (3w)
• BioAge Labs Begins Phase 1 Trial of Oral NLRP3 Inhibitor for Obesity (3w)
• Generative AI Designs Novel Antibiotics Against MRSA and Drug-Resistant Gonorrhea (3w)
• Owkin to Bring Agentic AI into Vienna’s Oncology Ecosystem (3w)
• Kriya Raises $313 Million to Advance Gene Therapy Programs (3w)
• AI Drug Developer Insilico Medicine Readies Brain-Penetrant Therapy For Parkinson’s Trials (3w)

Drug Channels

• Drug Channels Leadership Forum 2026: Full Agenda Now Available (Spoiler: Even more awesome than 2025!) (22h)
• If Banks Sync Data in Real Time, Why Can't Patient Services? (5d)
• Hubs: The Bridge Between Patients and Providers (2w)
• Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It (3w)
• Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes (3w)
• Solving the Gross-to-Net Bubble With Better Data (4w)
• Solving the Gross-to-Net Bubble with Better Data (4w)
• Pharmacy Shakeout: Why U.S. Drugstores Are Disappearing (4w)
• Patient Support’s Perfect Storm in 2025: Hits, Misses, and Surprises (1mo)
• Markup Madness 2025: Hospitals, Insurers, and the Broken Buy-and-Bill Market for Biosimilars (1mo)
• The AI Advantage: Evolving Patient Engagement Strategies to Improve Outcomes (1mo)
• Drug Channels News Roundup, July 2025: 340B vs. Patients, Humira Whiplash, Accumulator Fallout, and Pharmacy Struggles (1mo)
• Beyond Throughput: Building Reverification Strategies That Safeguard Access (1mo)
• 2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (1mo)
• Informa Connect’s Medicaid Drug Rebate Program Summit (1mo)
• Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (1mo)
• Rewriting the Access Script: A Pharmacist’s View on the Rise of Direct-to-Patient (2mo)
• The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market (2mo)
• Drug Channels News Roundup, June 2025: PBM Rebate Flow, 340B’s 2024 Boom, IRA Fallout, MFN Legal Risks—and Mark Cuban’s PBM Rant (2mo)
• Transparency vs. Reality: Troubling Lessons from PBM Disclosure Laws (rerun) (2mo)

• Servier acquires Kaerus Bioscience’s FXS candidate for US$450m (21h)
• NRG Therapeutics Ltd bags £50m in Series B financing (1d)
• BioFlo® 120 – Performance Meets Value (2d)
• BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla (2d)
• Alt protein: EASAC sees immediate need for action (2d)
• Microbiome play MRM Health NV raises €55m in Series B (5d)
• Novartis AG invests US$200m in lacklustre Parkinson’s target (6d)
• Cytokinetics’ Aficamten with breakthrough Phase III results (7d)
• Polpharma Biologics secures distribution of upcoming biosimilars (1w)
• Genentech inks US$400m IBD deal with OMass Therapeutics (1w)
• Sanofi receives US approval for oral ITP blockbuster (1w)
• PROTACs and MGDs: The Revolutionary Modalities for Drug Discovery (1w)
• SitalaBio pays US$670m for Fosun inflammation blocker (2w)
• Lilly’s weight loss pill orforglipron meets primary Phase III endpoint (2w)
• Calluna Pharma starts efficacy test with unique IPF antibody (2w)
• Novartis secures US$30m+ licence option from BioArctic (2w)
• About POWTECH TECHNOPHARM (2w)
• Alzheimer’s antibody Lecanemab launched in the EU (2w)
• US and EU confirm tariff deal on pharmaceuticals, generics largely exempt (3w)
• New Head of Development (3w)

Drug Hunter

• PF-07293893 (5h)
• Lessons in LAI: Discovery of a Long-Acting Injectable TAK1 Inhibitor (1d)
• Glossary: AI for Drug Discovery (1d)
• Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake (4d)
• PF-07853578 (5d)
• darovasertib (NYP-LXS196, IDE-196) (6d)
• Drug-Induced Phospholipidosis (6d)
• sevabertinib (BAY 2927088) (1w)
• zongertinib (BI 1810631) (1w)
• Opposing Views of the Immunology Target NEK7 (2w)
• avapritinib (2w)
• RBM39: A Second Wave of Molecular Glue Degraders (2w)
• MD-4251 (2w)
• brensocatib (2w)
• July 2025 Patent Highlights (2w)
• admilparant (BMS-986278) (3w)
• Target Selection: Lessons From Industry (3w)
• ACS Fall 2025 First Time Disclosures (3w)
• RNA-Targeting Small Molecules in Oncology: A Promising Solution to “Undruggable” Transcription Factors (3w)
• oveporexton (TAK-861) (3w)

• Top biotech deals in August 2025 (13h)
• Advanced expression vector design to overcome challenges in developing multichain biotherapeutics (18h)
• With Lykos CRL now public, FDA opens new era of accountability (1d)
• Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer? (4d)
• Navigating the biotech development journey from first steps to global scale with Lonza (4d)
• Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand (6d)
• How are biotechs tackling malaria? (6d)
• The biggest biotech funding rounds in August 2025 (1w)
• Blood Cancer Awareness Month: What biotech holds in store (1w)
• Can genetically modified crops help us adapt to climate change? (2w)
• A Finnish biotech is making progress on Parkinson’s disease with support from The Michael J. Fox Foundation (2w)
• Zemcelpro, the first blood cord expansion therapy to reach the EU market (2w)
• Five biotech companies in South Korea you should know about (2w)
• The Sanofi pipeline in 2025: Is the play-to-win strategy working? (3w)
• How RNAi is expanding from a therapy of choice for rare disease into treating common conditions (3w)
• From pasture to lab: The new biotech toolkit for cattle (3w)
• 10 biotech companies you should know about in Spain (3w)
• mRNA vaccine funding cuts: the impact on U.S. healthcare and biotech (3w)
• How biotech is improving the life of your cat (4w)
• Are next-generation psychedelics the way forward for addressing treatment resistant depression? (4w)

Bio IT World

• First-in-Class Dietary Supplement a Potentially Big Win for Babies (11h)
• Microbiome-Based Therapies Hold Promise for Chronic Diseases (5d)
• Psilocybin Being Investigated as an Anti-Aging Agent (6d)
• Machine Learning Penetrance Score Predicts Genetic Variant Impacts (1w)
• Ultima’s ppmSeq Pushes Sequencing to New Levels of Accuracy (2w)
• Follow the Money: Rheumatoid Arthritis Therapy, Novel Next-Gen Biosensor, More (2w)
• BioMed X, Novo Nordisk Collaboration, 10x Genomics Launches Platform Addition, More (2w)
• Bioprocessing Summit Honors LISURE as Best of Show Winner (3w)
• Family-Based Genomics Benchmark Promises More Accurate Variant Detection (3w)
• Nature’s Most Promising Bioactives to Speed Up Evidence-Based Drug Discovery (3w)
• Open-Source Medical Device Platform Aims to Accelerate Time to Market (4w)
• AI-Powered Cell Mapping Platform Accelerates Biotech Research and Drug Development (4w)
• AI in Medicine Making and Healthcare: Finding the Balance (4w)
• Russia Targets National Database of 1 Million Genomes by 2030 (1mo)
• New Research and Pipeline Updates at Alzheimer’s Conference (1mo)
• XProteome Launches with AI-Powered Protein Corona Platform for Disease Detection (1mo)
• Longitude Prize on ALS Launches, UK Biobank Completes World’s Largest Whole Body Imaging Project, More (1mo)
• Follow the Money: Universal Flu Vaccine, Full-Length Single-Molecule Protein Sequencer, More (1mo)
• Arab Pangenome Reference Published (1mo)
• Multiomics Platform Integration Advances Cancer Treatment Predictions (1mo)

• MRI Technique Detects Brain Iron, Indicates Risk of Cognitive Decline (4h)
• Alzheimer’s Vaccine Candidate ALZ-101 Begins Phase II Clinical Study (14h)
• Servier Buys Fragile X Syndrome Candidate for up to $450M (1d)
• Prior Dengue Infection Rewires Immunity, Boosts Vaccine Response (1d)
• Flu Severity in Older Adults Mediated by ApoD Regulation of Innate Antiviral Immunity (1d)
• Cancer Cells Use Backup Routes to Fuel Their Growth (1d)
• People Power in AI’s Penetration in Bioprocessing (1d)
• Public Model for Predicting Long-Term Cell Stability (1d)
• Tech and Teamwork Key to Building CGT Capacity in Smaller Markets (1d)
• Clarification Contributes More to CQA Than Realized (1d)
• Precision Microfluidics for RNA and Gene Therapy Applications (1d)
• Fentanyl-Hunter: Machine Learning–Driven Screening for Opioid Metabolites (2d)
• StockWatch: Ionis Scores on Phase III Data for Olezarsen (2d)
• Host Proteins Identified in SARS-CoV-2 Replication Pathways Reveal Drug Targets (4d)
• Spaceflight Aging of Human Stem Cells May Guide Cancer and Age-Related Disorder Modeling (4d)
• Beyond the Bioinformatics Hype: How to Build Scalable, AI-Driven Tools That Deliver in Precision Medicine (4d)
• Gilead Sciences Breaks Ground on New Biomanufacturing Hub (4d)
• Developing New Therapies Through Partnership, Electricity, and Immunotherapy (4d)
• High-Throughput Antibody Platform May Transform Therapeutic Discovery (5d)
• Structural Swaps in SCORE Protein Enable Programmable Pathogen Recognition in Plants (5d)

• FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer (5h)
• Change of Season Musings As A Breast Cancer Survivor (6h)
• Lunsumio plus Polivy Associated With Responses in MCL (7h)
• Standing Up to Cancer with Lynch Syndrome (9h)
• Zidesamtinib Elicits Responses in ROS1-Positive NSCLC (10h)
• Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC (11h)
• Suleika Jaouad on Why Self-Advocacy Matters for Patients With Cancer (13h)
• The Seasons of Cancer (1d)
• What Patients With Lung Cancer Need to Know About KRAS G12C Mutations (1d)
• Ivonescimab Plus Chemo Delays NSCLC Progression (1d)
• Standing Up to Cancer on My Own Two Feet (1d)
• FLAURA2 Shows Tagrisso Plus Chemo Boosts Survival in EGFR+ Lung Cancer (1d)
• FDA Grants Orphan Drug Designation to BA-101 in Glioblastoma (1d)
• Ifinatamab Deruxtecan Shows Activity in Previously Treated ES-SCLC (1d)
• Tagrisso With Chemotherapy Improves Survival in EGFR+ NSCLC (2d)
• Iza-bren Plus Tagrisso May Offer a New Option for Advanced Lung Cancer (2d)
• Dispelling Myths and Raising Awareness of Lung Cancer Risk (3d)
• Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma (3d)
• Venclexta And Azacitidine Fail to Improve MDS Survival (4d)
• What Does a Blood Cancer Diagnosis Mean? (4d)

Contract Pharma*

• Packaging Innovation with Purpose (6h)
• Medable Launches Agent Studio (8h)
• Abselion Launches AAVX and AAV9 Quantification Kits (8h)
• Parexel Establishes New Global HQ in Raleigh, NC (9h)
• Circle Pharma Partners with Eli Lilly to Boost AI-Driven Drug Discovery (11h)
• Ethris & Evonik Join Forces to Advance Targeted mRNA Vaccines and Therapies (12h)
• Inizio Taps Ryan Quigley as CEO (12h)
• Scenic Biotech Appoints Roland W. Bürli Chief Scientific Officer (13h)
• Novartis to Acquire Tourmaline Bio for $1.4 Billion (13h)
• Maximizing Bioavailability and Commercial Success with Softgels (1d)
• ElevateBio Names Larry Lockwood as Chief Commercial Officer (1d)
• CMP Scientific Appoints Darlene Solomon to Advise on Strategy & Technology (1d)
• Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (1d)
• KBI Biopharma, Infinimmune Partner to Support Antibody Manufacturing (1d)
• Servier to Acquire Kaerus Bioscience’s Autism Drug in Potential $450M Deal (1d)
• GXP-Storage Expands Global Reach with New U.K. Site (1d)
• Mission Pharmacal CMDO Invests in Infrastructure Enhancements (4d)
• One2Treat Raises Capital with Seed Extension (4d)
• Gilead Announces Partnership With PEPFAR (4d)
• Gannet BioChem Promotes Bob Rodebaugh to VP of Technology (4d)

• Quotient Sciences and CPI launch RNA drug development venture (17h)
• Bluejay begins phase 3 trial of brelovitug for hepatitis D (17h)
• Eisai unveils promising phase 1b data for narcolepsy drug E2086 (1d)
• AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 (5d)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (6d)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (6d)
• Polpharma Biologics and MS Pharma partner to expand biosimilar access (1w)
• eXmoor and Anthony Nolan partner to streamline cell therapy development (1w)
• FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease (1w)
• Lilly receives UK approval for pirtobrutinib in relapsed blood cancers (1w)
• Akiram advances trial of targeted radiotherapy for solid tumours (2w)
• Coya Therapeutics to progress trial of ALS treatment upon FDA approval (2w)
• Encare’s ERAS system gains Mayo Clinic qualification, strengthening global reach (2w)
• Johnny Cheng appointed as interim CEO of HUTCHMED (2w)
• Novartis blood disorder drug shows promise in late-stage trial (2w)
• Anne White to retire as head of Lilly Neuroscience after three decades at company (2w)
• ANGLE partners with Myriad Genetics to explore blood-based cancer testing (3w)
• Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data (3w)
• Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford (3w)
• FDA grants Breakthrough Therapy Designation to lung cancer therapy (3w)

• Strive Health Secures $550M to Advance Value-Based Kidney Care Model (4h)
• Corewell Health Touts Success of Virtual Lifestyle Medicine Program with Nudj Health (5h)
• Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds (6h)
• The Most Powerful Tool in Healthcare Marketing: A Patient’s Voice (12h)
• From Hospital to Home Without the Headaches: How Technology Can Smooth the Transition (13h)
• Judge Advances Particle Health’s Antitrust Lawsuit Against Epic (1d)
• Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels (1d)
• WeightWatchers Introduces New Menopause Program (1d)
• Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt (1d)
• Why Hormone Health Should Be A Standard Part Of Men’s Healthcare (1d)
• SOAR Act Would Help Individuals Relying on Oxygen Thrive (1d)
• How Can Payers Use Tech to Their Best Advantage? (1d)
• Why a US Judge Paused Several Provisions of the Marketplace Rule (2d)
• Trump’s Health Data Plan Could Hand Big Tech The Keys —And Lock Out Startups (2d)
• The Hidden Crisis in Serious Illness Care and How We Fix It (2d)
• Hello Patient Secures $22.5M for Conversational AI Solution (4d)
• Payment Integrity is a Systems Problem, not a Data Glitch (4d)
• ChatGPT for Medical Use Is a Cry for Help. We Need Better Medical Triage (4d)
• What Direction is Healthcare Navigation for Self-Insured Employers Moving? (4d)
• Healthcare Experts Slam Florida’s Plan to End Vaccine Mandates (5d)

• Nobel laureate David Baltimore dies at 87 (7h)
• Opinion: Exploitation persists in academic science—here’s what we can do (7h)
• Business briefing for September 9 (8h)
• Greening Chemistry: Don’t let resistance to change stop students from changing the world (9h)
• Manganese edges into the realm of noble-metal photochemistry (10h)
• Joseph S. Francisco named 2025 Pauling Medal Award winner (10h)
• Scientists uncover weakness in brain cancer’s armor (1d)
• Scientists in Congress: 50 years of ACS Public Policy Fellowships (1d)
• For director-at-large: Anna Cavinato (1d)
• For director-at-large: Malika Jeffries-EL (1d)
• For director-at-large: Donna Friedman (1d)
• For director-at-large: Will Lynch (1d)
• For District IV director: Milagros Delgado (1d)
• For District II director: Mary Engelman (1d)
• 2025 candidates’ election statements and backgrounds (1d)
• For president-elect: Christina C. Bodurow (1d)
• For District IV director: Lisa Houston (1d)
• For president-elect: Dawn Mason (1d)
• For District II director: Kimberly Agnew-Heard (1d)
• Chemistry is no catwalk (1d)

The Pharma Letter*

• Scenic Biotech names Roland Bürli as CSO (10h)
• Patients the ‘North Star’ for Sionna-bound Caroline Stark Beer (10h)
• Brinsupri massively overpriced at current rates, claims ICER (11h)
• Novartis to acquire Tourmaline Bio (12h)
• FDA rejection leaves Saol searching for a path forward in rare pediatric disease (13h)
• Congruence Therapeutics (13h)
• Rapport rockets on positive trial data for RAP219 (13h)
• Lilly rises on ‘striking and provocative’ Jaypirca results (14h)
• LB Pharma targets $250 million raise in bold IPO move (14h)
• Sandoz and Regeneron settle aflibercept dispute, paving way for US debut (15h)
• Arena BioWorks appoints Harvey Berger as CEO and shifts focus to biologics (15h)
• Chinese biotechs face new challenges in advanced therapies (15h)
• FDA issues two biosimilar final guidances to industry (16h)
• First disclosure of Phase II data for pumitamig (16h)
• India proposes faster drug approval process, cuts license timeline to 45 days (16h)
• Braveheart Bio (16h)
• M&A roundup - August 2025 (1d)
• Larry Lockwood named ElevateBio CCO (1d)
• Ozempic price cut to slow consumer shift toward alternatives (1d)
• Servier acquires KER-0193, a potential treatment for Fragile X syndrome (1d)

• FDA Approves Intravesical Gemcitabine Delivery for Bladder Cancer (5h)
• Talquetamab Dose Modification Maintains Efficacy in Multiple Myeloma (7h)
• FDA Grants Breakthrough Therapy Designation to Olomorasib is KRAS G12C NSCLC (9h)
• I-DXd Shows Promise in Treating Extensive-Stage SCLC (11h)
• FDA Grants Orphan Drug Designation to Novel Glioblastoma Therapy (12h)
• Dr Mikhael on the State of Myeloma Research Funding in 2025 (13h)
• Future Directions and Conclusion (14h)
• Deciding When and How to Add Therapy for Steroid-Refractory GVHD (1d)
• Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence (1d)
• Frontline Osimertinib/Chemo Betters OS in EGFR+ Advanced NSCLC (1d)
• Taletrectinib's Sustained Efficacy in Advanced ROS1-Positive NSCLC (1d)
• Interim Phase 2 Data for Cancer Anorexia-Cachexia Treatment Show Promise (1d)
• Pirtobrutinib Improves Survival in Treatment-Naive CLL/SLL (1d)
• Treatment Decision and Conclusion (1d)
• Analyses of the NAPOLI-3 Trial (1d)
• Azacitidine, Ruxolitinib Pairing Highlighted in Advanced MPN (1d)
• The BOT/BAL Breakthrough: A New Era for Colorectal Cancer Treatment (2d)
• The Targeted Pulse: Oncology Updates You Need to Know (2d)
• Challenging CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer (3d)
• The Role of Invasive Disease-Free Survival in Breast Cancer Research (3d)

• Degunkification (5h)
• Silent RNA (1d)
• An Underappreciated Fate of Drugs in Vivo (4d)
• Stirring Bars are Superstition? (5d)
• Nuclear Fusion in Palladium Metal. No, Really. (6d)
• A Condensate Dissolver (1w)
• RFK Jr. Must Go. And He's Not the Only One. (2w)
• Go Make Me Fifty Kilos of This Stuff (2w)
• Lithium Orotate Revisited (2w)
• When Do You Need a Macrocycle, Anyway? (3w)
• Cranking Up Protein Expression to the Limit (3w)
• Carbamorphine And More (3w)
• Kakistocracy (3w)
• Journal Impact Nonsense (4w)
• The Frontiers of Structure (4w)
• Lithium Deficiency and Alzheimer's Disease (4w)
• Microglia to the Rescue (1mo)
• In Praise of Weirdness (1mo)
• An mRNA Crime (1mo)
• Scaling Down and Back Up Again (1mo)

• HHS, FDA drop major DTC advertising policy changes (48m)
• Lilly lines up Julianne Moore to front brain health campaign (8h)
• Lundbeck retreats from dozens of markets, slashing staff (9h)
• Lilly offers AI discovery models to biotech partners (10h)
• ICER says GLP-1s 'still have serious affordability issues' (11h)
• Lilly eyes earlier use of blood cancer drug Jaypirca (14h)
• NHS trust league tables arrive in UK health shakeup (15h)
• US anti-vaccine rhetoric trumpeted in UK, thanks to Reform (16h)
• After a long biotech IPO lull, LB Pharma chances its arm (17h)
• Novartis nabs cardio drug with $1.4bn Tourmaline buy (18h)
• Mixed data from lung cancer trials on show at WCLC (1d)
• FDA lends a hand to Novo, Lilly on illegal GLP-1 imports (1d)
• NRG raises £50m to start trials of Parkinson's, ALS drug (1d)
• Servier bets $450m on Fragile X syndrome drug (1d)
• Massachusetts bucks HHS, issuing its own COVID guidelines (4d)
• Poll paints picture of menopause discrimination at work (4d)
• FDA releases previously unseen CRLs in transparency push (4d)
• Treeline's $200m Series A extension, and other biofinancings (4d)
• RFK faces bipartisan pressure at fractious hearing (5d)
• Remedy Meds buys telehealth rival in $500m marriage (5d)

• New NICE thresholds is good news for ultra-rare disease drugs, says biotech (10h)
• Registration open for DDW Symposium in London (12h)
• Transforming drug discovery with AI and digital labs: Last chance to register (18h)
• Treatment for post-natal depression authorised in UK (1d)
• From knowledge to creation: keeping up with AI (1d)
• UK immigration system is a barrier to cancer research, says CRUK (1d)
• Webinar: Challenges and solutions in CGT drug discovery (1d)
• This week in drug discovery 1-5 September (4d)
• Research programme represents a “new frontier in vaccine science” (4d)
• Advancing gene-agnostic therapies for inherited retinal diseases (4d)
• Advance your flow cytometry research with spectral flow protocols (5d)
• New podcast: Redefining the future with plant-based therapeutics (5d)
• Redefining the future with plant-based therapeutics (5d)
• Webinar: Uncover exciting new applications for your data (5d)
• Microenvironment switches cancer cells to a drug-resistant state (5d)
• FDA approves first BTK inhibitor for immune thrombocytopenia (6d)
• Baxdrostat offers hope for stubborn high blood pressure (6d)
• The evolution of chemical collections and drug-like diversity (6d)
• Webinar explores PROTAC-Mediated CDK2 degradation in oncology (6d)
• Novo and Replicate partner on srRNA therapies for obesity (1w)